STOCK TITAN
  1. Home
  2. News
  3. IPHA

Innate Pharma - IPHA STOCK NEWS

Welcome to our dedicated news page for Innate Pharma (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Innate Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Innate Pharma's position in the market.

News
Innate Pharma Announces Its Participation to Upcoming Investor Conference
Rhea-AI Summary
Innate Pharma (IPH; IPHA) to participate in Leerink Partners Global Biopharma Conference 2024 in Miami, Florida from March 11-13, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
conferences
-
News
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024
Rhea-AI Summary
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as at January 1, 2024: Total number of shares outstanding: 80,860,563 ordinary shares, 6,509 Preferred Shares 2016, 7,581 Preferred Shares 2017. Total number of theoretical voting rights: 81,617,753. Total number of exercisable voting rights: 81,599,178.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
News
Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
Rhea-AI Summary
Innate Pharma SA (IPH; IPHA) announced that the FDA has lifted the partial clinical hold on the lacutamab clinical program. The hold was placed after a patient death in the TELLOMAK study, initially thought to be due to a rare hematologic disorder. The FDA determined the death was related to disease progression and unrelated to the treatment. The lacutamab program continues following positive results in Sézary syndrome and plans to share final data in Mycosis Fungoides.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
none
News
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
Rhea-AI Summary
Innate Pharma SA (IPH; IPHA) strengthens leadership and corporate governance with the appointment of two new Executive Board members. Hervé Brailly, interim CEO, welcomes Arvind Sood as EVP, President of US Operations, and Dr. Sonia Quaratino as EVP, Chief Medical Officer to the Executive Board. Yannis Morel broadens his remit to Chief Operating Officer. The Company is positioning itself for future success by expanding its footprint in the US market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
management
-
News
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
Rhea-AI Summary
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced that Sanofi has exercised its option to license a natural killer (NK) cell engager program from Innate’s ANKET® platform. Sanofi will be responsible for all development, manufacturing, and commercialization of the program. Innate will receive a €15m payment for the exercise of this option and is eligible for up to €1.35bn in total milestones plus royalties on potential net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.8%
Tags
none
-
News
Innate Pharma Announces Leadership Change
Rhea-AI Summary
Innate Pharma SA (IPH; IPHA) CEO Mondher Mahjoubi resigns to join large pharmaceutical company. Hervé Brailly appointed interim CEO. Irina Staatz-Granzer named Chairwoman of the Supervisory Board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
management
News
Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023
Rhea-AI Summary
Innate Pharma SA (IPHA) and Sanofi are collaborating on SAR443579/IPH6101, a first-in-class NKp46/CD16-based NK cell engager targeting CD123. The drug demonstrated clinical benefit in patients with R/R AML, with 5 complete remissions achieved at 1 mg/kg and was well tolerated up to doses of 6 mg/kg. The updated efficacy and safety results were shared at the American Society of Hematology 2023 Annual Meeting, showing promising durable clinical efficacy with a favorable safety profile in various blood cancers. SAR443579 has FDA Fast Track Designation for the treatment of acute myeloid leukemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.43%
Tags
clinical trial
-
News
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
Rhea-AI Summary
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced positive final results from the Phase 2 TELLOMAK study in Sézary Syndrome patients. The global confirmed objective response rate (ORR) was 37.5%, with a median progression-free survival of 8.0 months. Lacutamab showed robust clinical activity and an overall favorable safety profile, with a virtual KOL event scheduled for Tuesday, December 12, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Innate Pharma to Host Virtual KOL Event on Lacutamab
Rhea-AI Summary
Innate Pharma SA (IPH; IPHA) announced a virtual KOL event on lacutamab, a first-in-class anti-KIR3DL2 antibody in development for cutaneous T-cell lymphoma and peripheral T cell lymphoma. Positive results from the TELLOMAK Phase 2 Trial with lacutamab in heavily pretreated patients with relapsed and refractory Sézary syndrome will be discussed at the American Society of Hematology (ASH) Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.31%
Tags
conferences
News
Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update
Rhea-AI Summary
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announces positive final results of lacutamab TELLOMAK Phase 2 trial in Sézary syndrome and preliminary data in Peripheral T Cell lymphoma to be presented at ASH Annual Meeting 2023. Cash position of €121.9 million1 as of 30 September 2023, expected cash runway into H2 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.66%
Tags
earnings
Stock IPHA logo
Innate Pharma

Nasdaq:IPHA

IPHA Rankings

#3777 Ranked by Market Cap
#1070 Ranked by Stock Gains
N/A Ranked by Dividends

IPHA Stock Data

200.70M
30.66M
0.11%
0.1%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
France
Marseille

About IPHA

innate pharma s.a. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immune system. innate pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body’s immune system to recognize and kill cancer cells. the company's broad pipeline includes four first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications with high unmet medical needs. innate pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of natural killer cell biology. this innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including astrazeneca, bristol-myers squibb, novo nordisk a/s and sanofi. innate pharma